1601
|
Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F, Fong S, van Lookeren Campagne M, Godowski P, Williams PM, Chan AC, Clark HF. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun 2005; 6:319-31. [PMID: 15789058 DOI: 10.1038/sj.gene.6364173] [Citation(s) in RCA: 286] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Immune cell-specific expression is one indication of the importance of a gene's role in the immune response. We have compiled a compendium of microarray expression data for virtually all human genes from six key immune cell types and their activated and differentiated states. Immune Response In Silico (IRIS) is a collection of genes that have been selected for specific expression in immune cells. The expression pattern of IRIS genes recapitulates the phylogeny of immune cells in terms of the lineages of their differentiation. Gene Ontology assignments for IRIS genes reveal significant involvement in inflammation and immunity. Genes encoding CD antigens, cytokines, integrins and many other gene families playing key roles in the immune response are highly represented. IRIS also includes proteins of unknown function and expressed sequence tags that may not represent genes. The predicted cellular localization of IRIS proteins is evenly distributed between cell surface and intracellular compartments, indicating that immune specificity is important at many points in the signaling pathways of the immune response. IRIS provides a resource for further investigation into the function of the immune system and immune diseases.
Collapse
Affiliation(s)
- A R Abbas
- Department of Bioinformatics, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1602
|
Abstract
The significance of type I interferons (IFN-alpha/beta) in biology and medicine renders research on their activities continuously relevant to our understanding of normal and abnormal (auto) immune responses. This relevance is bolstered by discoveries that unambiguously establish IFN-alpha/beta, among the multitude of cytokines, as dominant in defining qualitative and quantitative characteristics of innate and adaptive immune processes. Recent advances elucidating the biology of these key cytokines include better definition of their complex signaling pathways, determination of their importance in modifying the effects of other cytokines, the role of Toll-like receptors in their induction, their major cellular producers, and their broad and diverse impact on both cellular and humoral immune responses. Consequently, the role of IFN-alpha/beta in the pathogenesis of autoimmunity remains at the forefront of scientific inquiry and has begun to illuminate the mechanisms by which these molecules promote or inhibit systemic and organ-specific autoimmune diseases.
Collapse
|
1603
|
Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2005; 16:801-7. [PMID: 15511676 DOI: 10.1016/j.coi.2004.09.014] [Citation(s) in RCA: 172] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Recent studies of patients with systemic lupus erythematosus, together with data from lupus-prone mice, suggest that inappropriate activation of type I interferon might have a role in disease pathogenesis. Serum levels of IFN-alpha are elevated in SLE patients, and gene expression profiling of peripheral blood cells shows that most lupus cases demonstrate an upregulation of IFN-responsive genes. Of interest, the IFN gene 'signature' correlates with more severe disease. The available data support a model whereby chromatin-containing immune complexes circulating in the blood of lupus patients stimulate leukocytes to produce IFN, which perpetuates disease. These emerging insights into the connection between IFN and lupus provide a host of new diagnostic and therapeutic opportunities.
Collapse
Affiliation(s)
- Emily C Baechler
- Center for Lupus Research, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, USA.
| | | | | |
Collapse
|
1604
|
Nomenclature and classification in chronic childhood arthritis: time for a change? ACTA ACUST UNITED AC 2005; 52:382-5. [PMID: 15692991 DOI: 10.1002/art.20815] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
1605
|
Graham KL, Robinson WH, Steinman L, Utz PJ. High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 2005; 37:269-72. [PMID: 15518040 DOI: 10.1080/08916930410001710686] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Numerous groups have now validated high-throughput approaches to autoantibody profiling in a variety of systems. Recently, we have used autoantigen microarray technology to identify distinct autoantibody profiles in H-2 congenic MRL/lpr mice (Sekine et al., manuscript in preparation), and we are expanding this platform to study human and mouse models of IDDM and RA. We are also developing protein arrays for multiplex analysis of serum antibody isotypes. Multiplexed methods for autoantibody profiling will undoubtedly continue to uncover novel aspects of autoimmunity and B cell biology. It is now time to move these technologies beyond the proof-of-concept phase, and start addressing the next series of important questions. These include, but certainly are not limited to: identifying "autoantibody signatures" associated with disease state or outcome; profiling autoantibodies during the natural course of murine and human disease; and monitoring changes in autoantibody profiles of patients in response to therapeutic intervention. However, the next set of challenges is just right around the corner. As data and statistical analysis tools become more robust, it will be possible to generate and approach new hypotheses at an unprecedented pace.
Collapse
Affiliation(s)
- Kareem L Graham
- Division of Immunology and Rheumatology, Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA.
| | | | | | | |
Collapse
|
1606
|
Katz SI. The national bone and joint decade: impact for rheumatic diseases. ARTHRITIS AND RHEUMATISM 2005; 52:707-9. [PMID: 15751083 DOI: 10.1002/art.20933] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- Stephen I Katz
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892-2350, USA
| |
Collapse
|
1607
|
Sigurdsson S, Nordmark G, Göring HHH, Lindroos K, Wiman AC, Sturfelt G, Jönsen A, Rantapää-Dahlqvist S, Möller B, Kere J, Koskenmies S, Widén E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Rönnblom L, Syvänen AC. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76:528-37. [PMID: 15657875 PMCID: PMC1196404 DOI: 10.1086/428480] [Citation(s) in RCA: 440] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2004] [Accepted: 12/30/2004] [Indexed: 12/31/2022] Open
Abstract
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease caused by both genetic and environmental factors. Genome scans in families with SLE point to multiple potential chromosomal regions that harbor SLE susceptibility genes, and association studies in different populations have suggested several susceptibility alleles for SLE. Increased production of type I interferon (IFN) and expression of IFN-inducible genes is commonly observed in SLE and may be pivotal in the molecular pathogenesis of the disease. We analyzed 44 single-nucleotide polymorphisms (SNPs) in 13 genes from the type I IFN pathway in 679 Swedish, Finnish, and Icelandic patients with SLE, in 798 unaffected family members, and in 438 unrelated control individuals for joint linkage and association with SLE. In two of the genes--the tyrosine kinase 2 (TYK2) and IFN regulatory factor 5 (IRF5) genes--we identified SNPs that displayed strong signals in joint analysis of linkage and association (unadjusted P<10(-7)) with SLE. TYK2 binds to the type I IFN receptor complex and IRF5 is a regulator of type I IFN gene expression. Thus, our results support a disease mechanism in SLE that involves key components of the type I IFN system.
Collapse
Affiliation(s)
- Snaevar Sigurdsson
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Gunnel Nordmark
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Harald H. H. Göring
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Katarina Lindroos
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Ann-Christin Wiman
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Gunnar Sturfelt
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Andreas Jönsen
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Solbritt Rantapää-Dahlqvist
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Bozena Möller
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Juha Kere
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Sari Koskenmies
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Elisabeth Widén
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Maija-Leena Eloranta
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Heikki Julkunen
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Helga Kristjansdottir
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Kristjan Steinsson
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Gunnar Alm
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Lars Rönnblom
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| | - Ann-Christine Syvänen
- Molecular Medicine and Section of Rheumatology, Department of Medical Sciences, Uppsala University, and Department of Molecular Biosciences, Biomedical Center, Swedish University of Agricultural Sciences, Uppsala, Sweden; Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio; Department of Rheumatology, Lund University Hospital, Lund, Sweden; Division of Rheumatology, University Hospital, Umeå, Sweden; Department of Medical Genetics, University of Helsinki, and Department of Medicine, Peijas Hospital and Helsinki University Hospital, Helsinki; and Department of Rheumatology, Center for Rheumatology Research, Landspitalinn University Hospital, Reykjavik
| |
Collapse
|
1608
|
Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α Induces Early Lethal Lupus in Preautoimmune (New Zealand Black × New Zealand White)F1but Not in BALB/c Mice. THE JOURNAL OF IMMUNOLOGY 2005; 174:2499-506. [PMID: 15728455 DOI: 10.4049/jimmunol.174.5.2499] [Citation(s) in RCA: 225] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Recent studies indicate that IFN-alpha is involved in pathogenesis of systemic lupus erythematosus. However, direct proof that IFN-alpha is not only necessary, but also sufficient to induce lupus pathogenicity is lacking. In this study, we show that in vivo adenovector-mediated delivery of murine IFN-alpha results in preautoimmune (New Zealand Black (NZB) x New Zealand White (NZW))F(1), but not in normal, mice, in a rapid and severe disease with all characteristics of systemic lupus erythematosus. Anti-dsDNA Abs appeared as soon as day 10 after initiation of IFN-alpha treatment. Proteinuria and death caused by glomerulonephritis occurred in all treated mice within, respectively, approximately 9 and approximately 18 wk, at a time when all untreated (NZB x NZW)F(1) did not show any sign of disease. IFN-alpha in vivo induced an overexpression of B lymphocyte stimulator in circulation at similar levels in both the preautoimmune and the normal mouse strains. All effects elicited by IFN-alpha were dose dependent. (NZB x NZW)F(1) infused with purified murine IFN-alpha also showed acceleration of lupus. Thus, prolonged expression of IFN-alpha in vivo induces early lethal lupus in susceptible animals.
Collapse
Affiliation(s)
- Alexis Mathian
- Baylor Institute for Immunology Research, Dallas, TX 75204, USA
| | | | | | | | | |
Collapse
|
1609
|
Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A 2005; 102:3372-7. [PMID: 15728381 PMCID: PMC552921 DOI: 10.1073/pnas.0408506102] [Citation(s) in RCA: 395] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Cytokines, most particularly TNF and type I IFN (IFN-alphabeta), have been long considered essential elements in the development of autoimmunity. Identification of TNF in the pathogenesis of rheumatoid arthritis and TNF antagonist therapy represent successes of immunology. IFN-alphabeta plays a major role in systemic lupus erythematosus (SLE), a prototype autoimmune disease characterized by a break of tolerance to nuclear components. Here, we show that TNF regulates IFN-alpha production in vitro at two levels. First, it inhibits the generation of plasmacytoid dendritic cells (pDCs), a major producer of IFN-alphabeta, from CD34+ hematopoietic progenitors. Second, it inhibits IFN-alpha release by immature pDCs exposed to influenza virus. Neutralization of endogenous TNF sustains IFN-alpha secretion by pDCs. These findings are clinically relevant, as five of five patients with systemic juvenile arthritis treated with TNF antagonists display overexpression of IFN-alpha-regulated genes in their blood leukocytes. These results, therefore, might provide a mechanistic explanation for the development of anti-dsDNA antibodies and lupus-like syndrome in patients undergoing anti-TNF therapy.
Collapse
Affiliation(s)
- A Karolina Palucka
- Baylor Institute for Immunology Research, 3434 Live Oak Street, Dallas, TX 75214, USA
| | | | | | | | | |
Collapse
|
1610
|
Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. ACTA ACUST UNITED AC 2005; 52:201-11. [PMID: 15641052 DOI: 10.1002/art.20745] [Citation(s) in RCA: 171] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Cytotoxic T lymphocyte-mediated killing using granzyme B has recently been proposed to be a preferential and selective source of autoantigens in systemic autoimmune diseases, including systemic lupus erythematosus (SLE), while other reports have indicated that cytolytic activity in SLE patients was decreased. The aim of this study was to examine the phenotypic and functional status of the CD8+ T cells in SLE patients. METHODS Phenotype analysis of CD8+ T cells was carried out using flow cytometry. The cytotoxic potential of CD8+ T cells and its consequences were examined in redirected-killing experiments. SLE patients with quiescent disease (n = 41) were compared with SLE patients with active disease (n = 20), normal individuals (n = 36), and control patients with vasculitis (n = 14). Cytotoxic CD8+ T cell differentiation was examined by coculture with differentiated dendritic cells (DCs) in the presence of SLE patient sera. RESULTS Patients with disease flares were characterized by higher proportions of perforin- and/or granzyme B-positive lymphocytes with a differentiated effector phenotype (CCR7- and CD45RA+). The frequency of these cells in peripheral blood correlated with clinical disease activity as assessed by the SLE Disease Activity Index. These cells generated high amounts of soluble nucleosomes as well as granzyme B-dependent unique autoantigen fragments. Finally, the activation of DCs with serum from a patient with active lupus induced granzyme B expression in CD8+ T lymphocytes. CONCLUSION DCs generated in the presence of sera from SLE patients with active disease could promote the differentiation of CD8+ effector T lymphocytes that are fully functional and able to generate SLE autoantigens. Our data disclose a new and pivotal role of activated CD8+ T lymphocytes in SLE pathogenesis.
Collapse
Affiliation(s)
- Patrick Blanco
- CNRS-UMR5164 and IFR66, Université de Bordeaux 2, Place Amélie Raba Léon, 33076 Bordeaux, France.
| | | | | | | | | | | |
Collapse
|
1611
|
Abstract
Despite the longstanding interest and large number of publications on biomarkers in lupus, there are no validated and widely accepted biomarkers of systemic lupus erythematosus to date. To achieve the ultimate goal, to have a biomarker as a surrogate endpoint in clinical studies, candidate biomarkers have to first be validated in a statistically rigorous way. However, to qualify as a surrogate endpoint, even validated biomarkers have to go through a process that demonstrates that they accurately reflect a clinically important outcome. These goals can only be achieved in large multicenter, properly conducted studies. We reviewed the difficulties involved in developing validated biomarkers for systemic lupus erythematosus and summarized the available data on the most promising biomarker candidates of disease susceptibility and disease activity. We also report on the current status of a multicenter initiative to concentrate efforts of biomarker development.
Collapse
Affiliation(s)
- Gabor G Illei
- National Institutes of Health, Department of Health and Human Services, 10 Center Drive, Room 9S205, Bethesda, MD 20892, USA.
| | | |
Collapse
|
1612
|
Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MGE, Ly N, Woodward RN, Fry KE, Lau AYH, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. ACTA ACUST UNITED AC 2005; 50:3958-67. [PMID: 15593221 DOI: 10.1002/art.20798] [Citation(s) in RCA: 318] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To study the contribution of interferon-alpha (IFNalpha) and IFNgamma to the IFN gene expression signature that has been observed in microarray screens of peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE). METHODS Quantitative real-time polymerase chain reaction analysis of healthy control PBMCs was used to determine the relative induction of a panel of IFN-inducible genes (IFIGs) by IFNalpha and IFNgamma. PBMCs from 77 SLE patients were compared with those from 22 disease controls and 28 healthy donors for expression of IFIGs. RESULTS Expression of IFNalpha-inducible genes was significantly higher in SLE PBMCs than in those from disease controls or healthy donors. The level of expression of all IFIGs in PBMCs from SLE patients with IFNalpha pathway activation correlated highly with the inherent responsiveness of those genes to IFNalpha, suggesting coordinate activation of that cytokine pathway. Expression of genes preferentially induced by IFNgamma was not significantly increased in SLE PBMCs compared with control PBMCs. IFNalpha-regulated gene-inducing activity was detected in some SLE plasma samples. CONCLUSION The coordinate activation of IFNalpha-induced genes is a characteristic of PBMCs from many SLE patients, supporting the hypothesis that IFNalpha is the predominant stimulus for IFIG expression in lupus.
Collapse
Affiliation(s)
- Kyriakos A Kirou
- Hospital for Special Surgery, and Weill Medical College of Cornell University, New York, New York 10021, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1613
|
Utz PJ. Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus. Lupus 2005; 13:304-11. [PMID: 15230283 DOI: 10.1191/0961203303lu1017oa] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Validated biomarkers and surrogate markers are badly needed for monitoring patients with systemic lupus erythematosus (SLE), both for routine clinical care and for clinical trials research. SLE is difficult to study in clinical trials, in part because the disease is so heterogeneous. Very few useful markers have been identified, and even those that historically have been thought to be valid have been recently questioned. This report will focus on the use of emerging multiplexed assay formats that enable analysis of hundreds or even thousands of analytes simultaneously. Their potential and pitfalls for monitoring patients with SLE, particularly those enrolled in clinical trials testing novel therapeutics, will be discussed.
Collapse
Affiliation(s)
- P J Utz
- Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
| |
Collapse
|
1614
|
Tang Y, Schapiro MB, Franz DN, Patterson BJ, Hickey FJ, Schorry EK, Hopkin RJ, Wylie M, Narayan T, Glauser TA, Gilbert DL, Hershey AD, Sharp FR. Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. Ann Neurol 2005; 56:808-14. [PMID: 15562430 DOI: 10.1002/ana.20291] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Blood gene expression profiling has been applied to a variety of hematological malignancies, autoimmune disorders, and infectious diseases. This study applies this approach to genetic diseases without obvious blood phenotypes. Three genetic diseases including tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome were compared with a group of healthy controls. RNA from whole blood was surveyed using Affymetrix U133A arrays. Each disease was associated with a unique gene expression pattern in blood that can be accurately distinguished by a classifier. Genes on chromosome 21 were overexpressed in Down's syndrome, and genes controlling cell cycle and proliferation were associated with tuberous sclerosis complex type 2 or neurofibromatosis type 1. A subset of genes involved in cardiac development or remodeling were overexpressed in patients with Down's syndrome and congenital heart defects. These findings suggest that blood gene expression profiling on a broader basis might be useful for genetic disease screening/diagnosis and might help elucidate mechanisms and pathways that lead to genotype-phenotype differences.
Collapse
Affiliation(s)
- Yang Tang
- Department of Neurology and MIND Institute, University of California at Davis, Sacramento, CA, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1615
|
Datta SK, Zhang L, Xu L. T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens. J Mol Med (Berl) 2005; 83:267-78. [PMID: 15630591 DOI: 10.1007/s00109-004-0624-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2004] [Accepted: 11/16/2004] [Indexed: 12/22/2022]
Abstract
Special populations of T helper cells drive B cells to produce IgG class switched, pathogenic autoantibodies in lupus. The major source of antigenic determinants (epitopes) that trigger interactions between lupus T and B cells is nucleosomes of apoptotic cells. These epitopes can be used for antigen-specific therapy of lupus. Secondly, the autoimmune T cells of lupus are sustained because they resist anergy and activation-induced programmed cell death by markedly upregulating cyclooxygenase (COX) 2 along with the antiapoptotic molecule c-FLIP. Only certain COX-2 inhibitors block pathogenic anti-DNA autoantibody production in lupus by causing death of autoimmune T helper cells. Hence COX-2 inhibitors may work independently of their ability to block the enzymatic function of COX-2, and structural peculiarities of these select inhibitors may lead to better drug discovery and design.
Collapse
Affiliation(s)
- Syamal K Datta
- Department of Medicine, Feinberg School of Medicine, Northwestern University, 240 East Huron St., Chicago, IL 60611, USA.
| | | | | |
Collapse
|
1616
|
|
1617
|
Li J, Liu Y, Xie C, Zhu J, Kreska D, Morel L, Mohan C. Deficiency of type I interferon contributes toSle2-associated component lupus phenotypes. ACTA ACUST UNITED AC 2005; 52:3063-72. [PMID: 16200585 DOI: 10.1002/art.21307] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Studies in mice and humans have implicated type I interferon (IFN-I) in the pathogenesis of lupus. Given that the locus for IFN-I is positioned within the Sle2 murine lupus susceptibility interval on chromosome 4, we undertook this study to investigate whether differences in IFN-I levels might potentially contribute to the phenotypes ascribed to this locus. METHODS IFN-I, anti-IFN-I, isotype control antibody, or phosphate buffered saline was administered to C57BL/6 and B6.Sle2 mice, and the serologic and cellular phenotypes were studied. In addition, B6.Sle2 mice were examined for structural and expression polymorphisms in the IFN-I gene. RESULTS In both B6.Sle2 congenic mice and C57BL/6 control mice, antibody-mediated blockade of IFN-I augmented serum autoantibody levels and boosted B1a cell numbers. Administration of IFN-I ameliorated these 2 features previously attributed to this disease locus. Importantly, compared with B6 controls, B6.Sle2 mice had reduced levels of IFN-I in their sera and cell culture supernatants, following stimulation. Although several sequence polymorphisms were noted in the Sle2 alleles of various IFN-I genes, it was not established whether any of the noted sequence variations were causally related to the observed phenotypes. CONCLUSION Unexpectedly, reduction of IFN-I levels reproduced the serologic and cellular phenotypes previously associated with the Sle2 lupus susceptibility interval. Placing these findings in the context of other studies, the effect of IFN-I on systemic autoimmunity appears to be far more complex than originally perceived.
Collapse
Affiliation(s)
- Jianwei Li
- University of Texas Southwestern Medical School, Dallas 75390-8884, USA
| | | | | | | | | | | | | |
Collapse
|
1618
|
Debey S, Schoenbeck U, Hellmich M, Gathof BS, Pillai R, Zander T, Schultze JL. Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. THE PHARMACOGENOMICS JOURNAL 2004; 4:193-207. [PMID: 15037859 DOI: 10.1038/sj.tpj.6500240] [Citation(s) in RCA: 175] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Owing to its clinical accessibility, peripheral blood is probably the best source for the assessment of differences or changes in gene expression associated with disease or drug response and therapy. Gene expression patterns in peripheral blood cells greatly depend on temporal and interindividual variations. However, technical aspects of blood sampling, isolation of cellular components, RNA isolation techniques and clinical aspects such as time to analysis and temperature during processing have been suggested to affect gene expression patterns. We therefore assessed gene expression patterns in peripheral blood from 29 healthy individuals by using Affymetrix microarrays. When RNA isolation was delayed for 20-24 h-a typical situation in clinical studies-gene signatures related to hypoxia were observed, and downregulation of genes associated with metabolism, cell cycle or apoptosis became dominant preventing the assessment of gene signatures of interindividual variation. Similarly, gene expression patterns were strongly dependent on choice of cell and RNA isolation and preparation techniques. We conclude that for large clinical studies, it is crucial to reduce maximally the time to RNA isolation. Furthermore, prior to study initiation, the cell type of interest should already be defined. Our data therefore will help to optimize clinical studies applying gene expression analysis of peripheral blood to exploit drug responses and to better understand changes associated with disease.
Collapse
Affiliation(s)
- S Debey
- Molecular Tumor Biology and Tumor Immunology, Center for Internal Medicine, University of Cologne, Cologne, Germany
| | | | | | | | | | | | | |
Collapse
|
1619
|
Holers VM. Complement receptors and the shaping of the natural antibody repertoire. ACTA ACUST UNITED AC 2004; 26:405-23. [PMID: 15614507 DOI: 10.1007/s00281-004-0186-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2004] [Accepted: 10/12/2004] [Indexed: 10/26/2022]
Abstract
Complement and complement receptors have been known for several decades to play important roles in immune effector mechanisms related to pathogen elimination and tissue inflammation. In addition, studies over the last 10 years have clearly demonstrated a key role for the complement C3d activation fragment receptor designated CR2 (complement receptor type 2) in the switched-isotype, high-affinity and memory humoral immune responses to T-dependent foreign antigens. More recent studies have extended those observations to include a key role for CR2 and C3d in the humoral immune response to T-independent foreign antigens. Conversely, as these studies have proceeded, a parallel series of analyses have linked defects in expression or function of complement C4 and other classical pathway activation pathway proteins, as well as CR2 and the closely related CR1, to the loss of self tolerance to nuclear antigens such as double-stranded DNA and chromatin in systemic lupus erythematosus. With regard to the topic of this issue, it is now becoming increasingly clear that CR2 also plays a major role in the development of the natural antibody repertoire. Specifically, in the absence of this receptor natural IgM and IgG develop in the naïve animal that demonstrate clearly altered recognition patterns for specific natural antibody targets. This repertoire change is important physiologically in at least one setting because these CR2-dependent natural antibodies are necessary for the recognition of ischemic self tissues. In addition, it is possible that certain of the phenotypes manifest by CR2-deficient mice may be strongly influenced not only by effects on later stages of B cell activation and maturation, as commonly thought, but also by alterations in the pre-existing pool of natural antibodies that are influenced by this receptor. This review will examine the evidence that has accumulated over the last few years supporting these hypotheses.
Collapse
Affiliation(s)
- V Michael Holers
- Division of Rheumatology, Department of Medicine, B-115, University of Colorado Health Sciences Center, 4200 E. 9th Avenue, Denver, CO 80262, USA.
| |
Collapse
|
1620
|
Abstract
Human and mouse plasmacytoid dendritic cells have been shown to correspond to a specialized cell population that produces large amounts of type I interferons in response to viruses, the so-called natural interferon-producing cells. As a result, intensive investigation is now focused on the potential functions of plasmacytoid dendritic cells in both innate and adaptive immunity. Here we review recent progress on the characterization of plasmacytoid dendritic cell origin, development, migration and function in immunity and tolerance, as well as their effect on human diseases.
Collapse
Affiliation(s)
- Marco Colonna
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
| | | | | |
Collapse
|
1621
|
Devauchelle V, Chiocchia G. [What place for DNA microarray in inflammatory diseases?]. Rev Med Interne 2004; 25:732-9. [PMID: 15471599 DOI: 10.1016/j.revmed.2004.02.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2003] [Accepted: 02/02/2004] [Indexed: 11/21/2022]
Abstract
PURPOSE DNA chip is a recently developed technique allowing analysis of thousands of genes at the same time in multiple biological samples. In few years it has become an obligatory step in massive gene expression study. The enormous quantity of results generated and the new way of thinking allowed make this kind of study a true revolution. KEY MESSAGE AND RECENT FACTS The enormous discovery potential permitted by the accomplishment of multiple genomes sequencing and the advent of technologies allowing massive gene expression analyses have totally modified the diseases approach. Considering the obtainment of a real full picture of the transcriptional activity in an organ, tissue or cell is now legitimate. DNA microarray is obviously not the only technique allowing such type of analysis but it is without contest the technology which is the most popular and the one which has been recently the subject of the most important developments. It is certainly the technology which brought the main advances in tumour classification and discovery of new biomarkers. The first results based on this technology in inflammatory diseases have recently been reported. PERSPECTIVE AND PROJECTS The optimal use of DNA microarrays will necessitate a powerful statistical analysis and an high quality biological experimentation. Strict standard and quality criteria are developing. Obviously, the DNA chips have a role to play in multifactorial inflammatory diseases mainly through their potential to bring new answers to diagnostic and pathophysiological problems. One potential development of the technique in such diseases will be the definition of disease specific gene profiles and the generation of chips allowing the detection of few targeted genes with all the known mutations of these genes. The correlation of global or targeted gene expression with clinical and pathological data will allow a new step forward in the understanding and taking care of inflammatory diseases.
Collapse
Affiliation(s)
- V Devauchelle
- Unité Inserm 567, institut Cochin, pavillon Hardy-A, 1 étage, 27 rue du Faubourg-Saint-Jacques, 75674 Paris, France.
| | | |
Collapse
|
1622
|
Franchin G, Peeva E, Diamond B. Pathogenesis of SLE: implications for rational therapy. ACTA ACUST UNITED AC 2004. [DOI: 10.1016/j.ddmec.2004.11.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
1623
|
Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for sle. Nat Rev Drug Discov 2004; 3:1036-46. [PMID: 15573102 DOI: 10.1038/nrd1577] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
It is now widely accepted that the current standard of care for systemic lupus erythematosus (SLE) patients is inadequate. There has not been a new medication approved for this disease in thirty years. Attempts to develop and test new drugs have been ongoing since the mid-1990s, but have encountered formidable obstacles. Current models for lupus pathogenesis have provided a theoretical framework for understanding how heterogeneous genetic defects might combine in various ways to increase susceptibility to SLE in different individuals, and could have important implications for new drug development. With the current burst of drug discovery and increased public awareness of SLE, the impetus to overcome these obstacles has never been greater.
Collapse
Affiliation(s)
- Joan T Merrill
- Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 825 Northeast 13th Street Oklahoma City, Oklahoma 73104, USA
| | | | | |
Collapse
|
1624
|
Nath SK, Kilpatrick J, Harley JB. Genetics of human systemic lupus erythematosus: the emerging picture. Curr Opin Immunol 2004; 16:794-800. [PMID: 15511675 DOI: 10.1016/j.coi.2004.09.007] [Citation(s) in RCA: 112] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune inflammatory disease with partially understood etiology, which can affect virtually any organ. Despite suggestions to the contrary, SLE is proving to be a reliable phenotype for genetic studies. Similar to many other autoimmune diseases, SLE demonstrates a complex pattern of inheritance that is consistent with the involvement of multiple susceptibility genes as well as environmental risk factors. During the past several years, some new candidate genes have been implicated in induction of SLE through association studies, and multiple susceptibility regions have been detected through genome-wide linkage studies. Many of the susceptibility effects have been confirmed by independent studies.
Collapse
Affiliation(s)
- Swapan K Nath
- Arthritis and Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, Oklahoma 73104, USA.
| | | | | |
Collapse
|
1625
|
Mandel M, Gurevich M, Pauzner R, Kaminski N, Achiron A. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol 2004; 138:164-70. [PMID: 15373920 PMCID: PMC1809188 DOI: 10.1111/j.1365-2249.2004.02587.x] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Autoimmune diseases are either tissue-specific like multiple sclerosis (MS) or multisystemic like systemic lupus erythematosus (SLE), although clinically both exhibit common features. To gain insight into the properties of the genes involved in each disease we have investigated the gene expression signature of peripheral blood mononuclear cells (PBMC) in MS and SLE in comparison to healthy subjects. Total RNA was purified, hybridized to Genechip array and analysed in 36 subjects (13 relapsing-remitting MS patients, five SLE patients and 18 age-matched healthy subjects that served as controls). Additional blood samples from 15 relapsing-remitting MS patients, 8 SLE patients and 10 healthy subjects were used for confirmation of microarray gene expression findings by ELISA and RT-PCR. MS and SLE patients demonstrated a common gene expression autoimmune signature of 541 genes which differentiated them from healthy subjects. The autoimmune signature included genes that encode proteins involved in apoptosis, cell cycle, inflammation and regulation of matrix metalloproteinase pathways. Specifically, decreased TIMP1 gene expression in the autoimmunity signature suggests increased MMP activity in target tissues as a result of the lack of feedback mechanism. An additional different disease specific signature identified the gene expression pattern for MS (1031 genes), mainly associated with over-expression of adhesion molecules and down-expression of heat shock proteins; the SLE specific signature (1146 genes) mainly involved DNA damage/repair pathways that result in production of nuclear autoantibodies. These results provide insights into the genetic pathways underlying autoimmune diseases, and identify specific disease-associated signatures that may enable targetted disease-related specific therapies to be developed.
Collapse
Affiliation(s)
- M Mandel
- Blood Bank, Sheba Medical Centre, Tel Hashomer, Israel
| | | | | | | | | |
Collapse
|
1626
|
Qing X, Putterman C. Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2004; 3:505-9. [PMID: 15546798 DOI: 10.1016/j.autrev.2004.07.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2004] [Accepted: 07/06/2004] [Indexed: 11/20/2022]
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a complex pathogenesis involving multiple genetic and environmental contributions. DNA microarray technology has recently been applied to unravel some of this complexity through genomewide profiling. Early studies using microarray analysis of peripheral blood mononuclear cells (PBMCs) from SLE patients revealed dysregulation of inflammatory cytokines, chemokines, and immune response-related genes, as well as genes involved in apoptosis, signal transduction, and the cell cycle. More recently, using arrays containing many more genes, 4 independent research groups have found that interferon (IFN)-regulated genes are highly overexpressed in the peripheral blood and kidney glomeruli of SLE patients, supporting a crucial role for interferon in SLE. Future studies focusing on target tissues or organs in lupus, including the kidney, may further contribute to our understanding of lupus pathogenesis while providing new targets for therapy.
Collapse
Affiliation(s)
- Xiaoping Qing
- The Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | | |
Collapse
|
1627
|
Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist. J Immunother 2004; 27:460-71. [PMID: 15534490 DOI: 10.1097/00002371-200411000-00006] [Citation(s) in RCA: 161] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Subcutaneous injection of normal human volunteers with a B-class CpG oligodeoxynucleotide (ODN) TLR9 agonist, CPG 7909, induced a TH1-like pattern of systemic innate immune activation manifested by expression of IL-6, IL-12p40, IFN-alpha, and IFN-inducible chemokines. Serum IP-10 was found to be the most sensitive assay for subcutaneous CPG 7909 stimulation; its level was significantly increased in all subjects at all dose levels, including the lowest tested dose of just 0.0025 mg/kg. This pattern of chemokine and cytokine induction was markedly different from that previously reported to be induced by TLR9 stimulation in rodents, most likely reflecting species-specific differences in the cell types expressing TLR9. Subcutaneous CPG 7909 injection induced transient shifts in blood neutrophils, lymphocytes, and monocytes, consistent with the increased chemokine expression. Levels of acute phase reactants such as C-reactive protein were also increased. A second subcutaneous CPG 7909 injection administered 2 weeks after the first elicited similar immune responses, showing little or no tolerance to the effects of repeated in vivo TLR9 stimulation. Subjects developed dose-dependent transient injection site reactions and flu-like symptoms but otherwise tolerated injection well, with no evidence of organ toxicity or systemic autoimmunity. The activation of innate immunity was dependent on the route of ODN administration, since intravenous injection caused no such effects. These studies indicate that in vivo activation of TLR9 by subcutaneous administration of CPG 7909 could be a well-tolerated immunotherapeutic approach for induction of TH1 innate immune activation.
Collapse
Affiliation(s)
- Arthur M Krieg
- Coley Pharmaceutical Group, Wellesley, Massachusetts 02481, USA.
| | | | | | | | | |
Collapse
|
1628
|
Hueber W, Zeng D, Strober S, Utz PJ. Interferon-?-inducible proteins are novel autoantigens in murine lupus. ACTA ACUST UNITED AC 2004; 50:3239-49. [PMID: 15476221 DOI: 10.1002/art.20508] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To investigate the spectrum of B cell autoimmunity in the recently described anti-CD1-autoreactive T cell receptor (TCR)-transgenic murine lupus-like (CD1 lupus-like) model. METHODS Lethally irradiated BALB/c/nu/nu mice were injected intravenously with donor BALB/c bone marrow and spleen cells expressing TCRalpha and TCRbeta transgenes that recognize CD1d. Sera from adoptive host animals that developed lupus (i.e., CD1 lupus mice) were collected at serial time points and analyzed by Western blotting and immunoprecipitation, using protein extracts prepared from NIH3T3 mouse fibroblasts and EL-4 lymphocytes, respectively. Sera obtained from older animals in several models of spontaneous lupus (NZB/NZW, MRL++, and MRL/lpr mice), unmanipulated BALB/c/nu/nu mice, and normal BALB/c mice were used as controls. RESULTS Analyses demonstrated that the prominent targets of autoantibodies in the CD1 lupus-like model are interferon-alpha (IFNalpha)-inducible antigens. Biochemical and serologic characterizations identified one antigen as belonging to the interferon-inducible 202 (Ifi202) subfamily of proteins within the Ifi200 family, and a second antigen as a member of the 70-kd heat-shock protein family. Autoantibodies directed against these antigens were rapidly produced at an early stage of disease. Anti-p50 autoantibodies were present in sera from 7 (78%) of 9 CD1 lupus mice that developed severe kidney disease. CONCLUSION IFNalpha-inducible proteins represent a novel class of autoantigens in murine lupus, and the findings suggest additional roles for IFNalpha in this disease. Since Ifi202 autoantigens are encoded by the murine non-major histocompatibility complex lupus-susceptibility gene locus Ifi202, these data provide a link between recent advances in lupus genetics and the formation of autoantibodies.
Collapse
Affiliation(s)
- Wolfgang Hueber
- Stanford University School of Medicine, Stanford, California, 94305, USA
| | | | | | | |
Collapse
|
1629
|
Tassiulas I, Hu X, Ho H, Kashyap Y, Paik P, Hu Y, Lowell CA, Ivashkiv LB. Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat Immunol 2004; 5:1181-9. [PMID: 15467722 DOI: 10.1038/ni1126] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2004] [Accepted: 09/14/2004] [Indexed: 01/21/2023]
Abstract
A key function of interferons is priming multiple cell types for enhanced activation by cytokines and inflammatory factors, including tumor necrosis factor, bacterial lipopolysaccharide and interferons themselves. Here we show that interferon-alpha (IFN-alpha)-induced activation of the transcriptional activator STAT1 and inflammatory STAT1 target genes was enhanced in IFN-gamma-primed macrophages. Enhanced IFN-alpha signaling and proinflammatory function were dependent on the tyrosine kinase Syk and on adaptor proteins that activate Syk through immunoreceptor tyrosine activation motifs. Increased STAT1 expression contributed to enhanced IFN-alpha-induced STAT1 activation in primed macrophages. These results identify a mechanism by which crosstalk between cytokine and immune cell-specific immunoreceptor tyrosine activation motif-dependent signaling pathways regulates macrophage responses to IFN-alpha.
Collapse
Affiliation(s)
- Ioannis Tassiulas
- Arthritis and Tissue Degeneration Program, Department of Medicine, Hospital for Special Surgery, New York, New York 10021, USA
| | | | | | | | | | | | | | | |
Collapse
|
1630
|
Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. ACTA ACUST UNITED AC 2004; 50:2415-22. [PMID: 15334452 DOI: 10.1002/art.20353] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Joel Schiffenbauer
- Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20850, USA.
| | | | | | | |
Collapse
|
1631
|
Ivashkiv LB. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2004; 36:473-9. [PMID: 14984024 DOI: 10.1080/08916930310001605882] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Type I interferons (IFNs) are pleiotropic cytokines that have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). A key aspect of type I IFN biology is that previous exposure to type I IFNs alters subsequent cellular responses to extracellular stimuli. Type I IFNs may either prime cells for stronger responses to viruses, bacterial pathogens and cytokines such as IL-6 and IFN-gamma, or may suppress cellular responses to LPS and TNFalpha. Herein, we review type I IFN signal transduction via the Jak-STAT pathway, and mechanisms by which type I IFNs prime or suppress responses to environmental factors. We develop a hypothesis that type I IFN-dependent priming/enhancement of cellular responses to pro-inflammatory cytokines such as IFNgamma and IL-6 contributes to pathogenesis of SLE. In addition, cross-regulation between type I IFNs and TNFalpha and its potential role in SLE pathogenesis is discussed.
Collapse
Affiliation(s)
- Lionel B Ivashkiv
- Department of Medicine, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021, USA.
| |
Collapse
|
1632
|
Kono DH, Baccala R, Theofilopoulos AN. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 2004; 36:503-10. [PMID: 14984027 DOI: 10.1080/08916930310001624665] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Type I interferons (IFN-alphabeta) are immunoregulatory cytokines that promote both innate and adaptive immune responses. Although they have been implicated in human SLE, recent studies in mice have helped solidify this connection. By using lupus-prone mice with knockout of the IFN-alphabeta receptor, we and others have documented that lack of IFN-alphabeta leads to a marked reduction in disease manifestations, including autoantibody production, target organ damage and mortality. Furthermore, IFN-alphabeta was found to potentially contribute to several levels of disease pathogenesis. These included the differentiation and activation of dendritic cells, the activation and proliferation of T cells, T cell survival and the activation and survival of autoantibody-producing B cells. These findings strongly support the targeting of IFN-alphabeta in SLE and suggest that definition of the specific pathways critical for disease induction will be important for optimal intervention.
Collapse
Affiliation(s)
- Dwight H Kono
- Department of Immunology/IMM3, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA.
| | | | | |
Collapse
|
1633
|
Abstract
Altered regulation of interferon-alpha (IFNalpha) in systemic lupus erythematosus (SLE) was first demonstrated nearly 25 years ago. However, only recently has due attention been directed towards the central role of this cytokine family in SLE. Several laboratories have used large-scale microarray technology to study global gene expression patterns in heterogeneous populations of peripheral blood cells from lupus patients and control subjects. The results of these studies demonstrate that IFN-regulated genes are among the most significantly overexpressed in SLE mononuclear cells. In view of the protean effects of IFNs on immune system function, increased activity of IFNs may account for many of the immune system alterations that characterize SLE and contribute to autoimmunity. Definition of the nature of the major IFNs, or other factors, that drive the IFN-regulated gene expression signature noted in SLE is an important area for investigation that may lead to new approaches to targeted therapy of SLE.
Collapse
Affiliation(s)
- Mary K Crow
- Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, 535 East 70th Street, New York, NY, USA.
| | | | | |
Collapse
|
1634
|
Moser KL, Gaffney PM, Grandits ME, Emamian ES, Machado DB, Baechler EC, Rhodus NL, Behrens TW. The use of microarrays to study autoimmunity. J Investig Dermatol Symp Proc 2004; 9:18-22. [PMID: 14870980 DOI: 10.1111/j.1087-0024.2004.00836.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
As with the development of any novel and potentially powerful technology, the prospect of revealing new information that may dramatically change our understanding of biological processes can generate much excitement. Such is true for the emerging genomic approaches that make possible high-density assays using microarray platforms. Indeed, it is difficult, if not impossible, to imagine any area of biology that could not be affected by the wide range of potential applications of microarray technology. Numerous examples, such as those from the field of oncology, provide striking evidence of the power of microarrays to bring about extraordinary advances in molecularly defining important disease phenotypes that were otherwise unrecognized using conventional approaches such as histology. However, only a few studies in autoimmunity are available to date. Very recent work in alopecia areata, multiple sclerosis, systemic lupus erythematosus, and Sjögren's syndrome illustrates the potential for gaining new insights into the pathophysiology of these complex autoimmune disorders on a global, molecular scale. These new insights are likely to significantly improve our understanding of disease processes, diagnosis, identification of new therapeutic targets, and identification of patients most likely to benefit from specific and tailored therapies.
Collapse
Affiliation(s)
- Kathy L Moser
- Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455, USA.
| | | | | | | | | | | | | | | |
Collapse
|
1635
|
Sharif MN, Tassiulas I, Hu Y, Mecklenbräuker I, Tarakhovsky A, Ivashkiv LB. IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. THE JOURNAL OF IMMUNOLOGY 2004; 172:6476-81. [PMID: 15128840 DOI: 10.4049/jimmunol.172.10.6476] [Citation(s) in RCA: 103] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Interleukin-10 is a predominantly anti-inflammatory cytokine that inhibits macrophage and dendritic cell function, but can acquire proinflammatory activity during immune responses. We investigated whether type I IFNs, which are elevated during infections and in autoimmune diseases, modulate the activity of IL-10. Priming of primary human macrophages with low concentrations of IFN-alpha diminished the ability of IL-10 to suppress TNF-alpha production. IFN-alpha conferred a proinflammatory gain of function on IL-10, leading to IL-10 activation of expression of IFN-gamma-inducible, STAT1-dependent genes such as IFN regulatory factor 1, IFN-gamma-inducible protein-10 (CXCL10), and monokine induced by IFN-gamma (CXCL9). IFN-alpha priming resulted in greatly enhanced STAT1 activation in response to IL-10, and STAT1 was required for IL-10 activation of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma expression in IFN-alpha-primed cells. In control, unprimed cells, IL-10 activation of STAT1 was suppressed by constitutive activity of protein kinase C and Src homology 2 domain-containing phosphatase 1. These results demonstrate that type I IFNs regulate the balance between IL-10 anti- and proinflammatory activity, and provide insight into molecular mechanisms that regulate IL-10 function. Gain of IL-10 proinflammatory functions may contribute to its pathogenic role in autoimmune diseases characterized by elevated type I IFN levels, such as systemic lupus erythematosus.
Collapse
Affiliation(s)
- M Nusrat Sharif
- Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY 10021, USA
| | | | | | | | | | | |
Collapse
|
1636
|
Abstract
PURPOSE OF REVIEW The purpose of this review is to provide an update on the clinical manifestations of SLE in children. Emerging clues on the pathogenesis of the disease based on recent human studies conducted both in children and adults, will also be summarized. RECENT FINDINGS Pediatric Rheumatologists caring for children with SLE face many challenges. As the life expectancy of these patients improves, new recognized complications such as accelerated atherosclerosis and hypertension emerge as major causes of morbidity. However, few longitudinal studies describing the long term outcome of these children, including the impact of disease and treatment on their physical and psychological development are available. Few prospective interventional studies have been carried out to assess the efficacy of established and novel treatments in the pediatric population. Recently, basic studies aimed at understanding the immune alterations underlying this disease have been performed in children. These studies indicate an important role for interferon-alpha (IFN-alpha) in the pathogenesis of this disease and reveal an overall striking homogeneity of leukocyte gene expression profiles in children and adults with SLE. The contribution of novel gene polymorphisms to disease susceptibility and the sequential breakdown of tolerance to nuclear antigens that precedes clinical manifestations in patients with SLE are among the recent studies that are helping us understand the complex SLE puzzle. SUMMARY SLE continues to cause significant morbidity in the pediatric age group. A better recognition of the age-specific manifestations and long-term complications of this disease is required to improve its outcome. Understanding its unique pathogenesis will hopefully lead to the development of better, more targeted and less toxic therapies.
Collapse
Affiliation(s)
- Dorothee Stichweh
- Baylor Institute for Immunology Research, Dallas, Texas, and the UT Southwestern Medical Center, Dallas, Texas, USA
| | | | | |
Collapse
|
1637
|
Abstract
PURPOSE OF REVIEW To describe the lines of evidence supporting a significant role for interferon-alpha (IFNalpha) in the pathogenesis of systemic lupus erythematosus (SLE) and to propose potential mechanisms by which IFNalpha contributes to the autoimmunity and immune dysfunction of SLE. RECENT FINDINGS Long-standing data indicating elevated levels of IFNalpha in the circulation of patients with SLE have recently been supplemented by reports from clinical practice, gene expression data, analysis of patient cells studied ex vivo, and studies of mechanisms of induction of IFNalpha production to provide complementary data strongly supporting a pathogenic role for IFNalpha in SLE. Recombinant IFNalpha, when administered as a therapy to patients with malignancy or hepatitis infection, can induce SLE. IFNalpha-regulated genes are highly expressed in SLE peripheral blood cells compared with cells from control subjects. Functional alterations of SLE mononuclear cells have been attributed to effects of IFNalpha. In addition, immune complexes bearing lupus autoantibodies and RNA or DNA have been shown to induce IFNalpha production. Finally, progress in understanding the role of Toll-like receptors (TLR) in the activation of the innate immune response has suggested potential mechanisms by which adjuvant-like factors act through TLR to induce IFNalpha as well as effective processing of self-antigens, resulting in activation of an adaptive immune response directed against self, as well as cytokine-mediated immune dysfunction. SUMMARY Substantial evidence supports a significant role for IFNalpha in the pathogenesis of lupus. The IFNalpha pathway represents a promising target for therapeutic intervention in patients with SLE.
Collapse
Affiliation(s)
- Mary K Crow
- Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.
| | | |
Collapse
|
1638
|
Rus V, Chen H, Zernetkina V, Magder LS, Mathai S, Hochberg MC, Via CS. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol 2004; 112:231-4. [PMID: 15308115 DOI: 10.1016/j.clim.2004.06.005] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2004] [Accepted: 06/04/2004] [Indexed: 12/31/2022]
Abstract
Systemic lupus erythematosus (SLE) is characterized by periods of flare and remission. The search for parameters associated with disease activity has been an area of intense investigation. To identify genes that best differentiate patients with active from those with inactive disease, the expression pattern of 375 genes was analyzed in peripheral blood mononuclear cells (PBMC) from 12 patients with active and 14 patients with inactive disease. Using the "nearest shrunken centroids" method, 29 genes were found to best discriminate the two groups. Among these genes, 14 were upregulated and 15 were downregulated in patients with active compared to those with inactive disease. Fourteen of these genes also correlated with SELENA-SLEDAI with correlation coefficients ranging from 0.4 to 0.7. Most of these genes have not been previously associated with disease activity and belong to a variety of families such as adhesion molecules, proteases, TNF superfamily, and neurotrophic factors. Using a cross-validation method, the error rate for classifying samples in the two groups was 30%. These results highlight the potential use of microarray data in identifying genes associated with disease activity in SLE, which could become potential biomarkers or future therapeutic targets.
Collapse
Affiliation(s)
- Violeta Rus
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
| | | | | | | | | | | | | |
Collapse
|
1639
|
Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. ACTA ACUST UNITED AC 2004; 50:2048-65. [PMID: 15248202 DOI: 10.1002/art.20345] [Citation(s) in RCA: 111] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Gabor G Illei
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, DHHS, Bethesda, Maryland 20892, USA.
| | | | | | | |
Collapse
|
1640
|
Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22:431-56. [PMID: 15032584 DOI: 10.1146/annurev.immunol.22.012703.104549] [Citation(s) in RCA: 371] [Impact Index Per Article: 18.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Complement has both beneficial and deleterious roles in the pathogenesis of systemic lupus erythematosus (SLE). On the one hand, patients with SLE present with decreased complement levels and with complement deposition in inflamed tissues, suggestive of a harmful role of complement in the effector phase of disease. On the other hand, homozygous deficiency of any of the classical pathway proteins is strongly associated with the development of SLE. There are two main hypotheses to explain these observations. The first invokes an important role for complement in the physiological waste-disposal mechanisms of dying cells and immune complexes. The second hypothesis is based around the role of complement in determining the activation thresholds of B and T lymphocytes, with the proposal that complement deficiency causes incomplete maintenance of peripheral tolerance. These two hypotheses are not mutually exclusive. In addition, there is evidence for a contribution from other genetic factors in determining the phenotype of disease in the absence of complement.
Collapse
Affiliation(s)
- Anthony P Manderson
- Rheumatology Section, Division of Medicine, Faculty of Medicine, Imperial College, Hammersmith Campus, London W12 0NN, United Kingdom.
| | | | | |
Collapse
|
1641
|
Abstract
Both the type I (IFN-alpha beta) and type II (IFN-gamma) IFNs have been heavily implicated in the pathogenesis of systemic lupus erythematosus. To test the relative roles of these systems, congenic lupus-prone MRL/CD95(lpr/lpr) (MRL/lpr) mice lacking the type I IFN receptor (IFN-RI), type II IFN receptor (IFN-RII), or both, were derived. As expected, deficiency for IFN-RII protected MRL/lpr mice from the development of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease. However, deficiency for the IFN-RI surprisingly worsened lymphoproliferation, autoantibody production, and end organ disease; animals doubly deficient for IFN-RI and IFN-RII developed an autoimmune phenotype intermediate between wild-type and IFN-RII-deficient animals, all correlating with an ability of type I IFN to suppress MRL B cell activation. Thus, type I IFNs protect against both the humoral and end organ autoimmune syndrome of MRL/lpr mice, independent of IFN-gamma. These findings warrant caution in the use of type I IFN antagonists in the treatment of autoimmune diseases and suggest further investigation into the interplay between the types I and II IFNs during the ontogeny of pathogenic autoantibodies.
Collapse
MESH Headings
- Animals
- Antibodies, Antinuclear/biosynthesis
- Autoimmune Diseases/genetics
- Autoimmune Diseases/pathology
- Autoimmune Diseases/physiopathology
- Autoimmune Diseases/prevention & control
- B-Lymphocytes/immunology
- Crosses, Genetic
- Disease Models, Animal
- Female
- Interferon-alpha/physiology
- Interferon-beta/physiology
- Kidney Glomerulus/pathology
- Liver/pathology
- Lung/pathology
- Lupus Erythematosus, Systemic/genetics
- Lupus Erythematosus, Systemic/pathology
- Lupus Erythematosus, Systemic/physiopathology
- Lupus Erythematosus, Systemic/prevention & control
- Lupus Nephritis/pathology
- Lupus Nephritis/physiopathology
- Lupus Nephritis/prevention & control
- Lymphocyte Activation
- Lymphoproliferative Disorders/genetics
- Lymphoproliferative Disorders/physiopathology
- Male
- Membrane Proteins
- Mice
- Mice, Inbred BALB C
- Mice, Inbred MRL lpr
- Receptor, Interferon alpha-beta
- Receptors, Interferon/deficiency
- Receptors, Interferon/genetics
- Receptors, Interferon/physiology
- Rheumatoid Factor/biosynthesis
- Salivary Glands/pathology
Collapse
Affiliation(s)
- Jonathan D Hron
- Department of Internal Medicine , Washington University School of Medicine, St. Louis, MO 63110, USA
| | | |
Collapse
|
1642
|
Nakashima H, Matsuno S, Akahoshi M, Miyake K, Inoue Y, Tanaka Y, Ninomiya I, Shimizu S, Igawa T, Sadanaga A, Otsuka T, Harada M. Association between IFNA genotype and the risk of systemic lupus erythematosus. Clin Rheumatol 2004; 24:38-40. [PMID: 15674657 DOI: 10.1007/s10067-004-0966-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2004] [Accepted: 05/10/2004] [Indexed: 11/29/2022]
Abstract
Systemic lupus erythematosus (SLE) is characterized by multisystem inflammation and production of autoantibodies, which can generate immune complexes and may cause tissue damage through the recognition of an autoantigen. Although many factors have been proposed, such as genetic factors, environmental factors, hormonal action, viruses, and dysregulation of cytokine production, the cause of this disease is not well understood. It has been reported that the levels of interferon (IFN)-alpha in the sera of some SLE patients are elevated and that IFN-alpha induces maturation of monocytes into highly active antigen-presenting dendritic cells (DCs). We analyzed the association between IFN-alpha genotype and the risk of SLE to clarify whether IFN-alpha plays a central role in susceptibility to SLE. The results showed that no IFN-alpha genotype was significantly associated with the risk of SLE.
Collapse
Affiliation(s)
- Hitoshi Nakashima
- Department of Medicine and Biosystemic Science, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, 812-8582 Higashi-ku, Fukuoka, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
1643
|
Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004; 113:1722-33. [PMID: 15199407 PMCID: PMC420500 DOI: 10.1172/jci19139] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2003] [Accepted: 04/09/2004] [Indexed: 11/17/2022] Open
Abstract
The molecular pathogenesis of focal/diffuse proliferative lupus glomerulonephritis was studied by cDNA microarray analysis of gene expression in glomeruli from clinical biopsies. Transcriptional phenotyping of glomeruli isolated by laser-capture microscopy revealed considerable kidney-to-kidney heterogeneity in increased transcript expression, resulting in four main gene clusters that identified the presence of B cells, several myelomonocytic lineages, fibroblast and epithelial cell proliferation, matrix alterations, and expression of type I IFN-inducible genes. Glomerulus-to-glomerulus variation within a kidney was less marked. The myeloid lineage transcripts, characteristic of those found in isolated activated macrophages and myeloid dendritic cells, were widely distributed in all biopsy samples. One major subgroup of the samples expressed fibrosis-related genes that correlated with pathological evidence of glomerulosclerosis; however, decreased expression of TGF-beta1 argued against its role in lupus renal fibrosis. Expression of type I IFN-inducible transcripts by a second subset of samples was associated with reduced expression of fibrosis-related genes and milder pathological features. This pattern of gene expression resembled that exhibited by activated NK cells. A large gene cluster with decreased expression found in all samples included ion channels and transcription factors, indicating a loss-of-function response to the glomerular injury.
Collapse
Affiliation(s)
- Karin S Peterson
- Department of Pediatrics, Columbia University, New York, New York 10032, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
1644
|
Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. ACTA ACUST UNITED AC 2004; 50:1861-72. [PMID: 15188363 DOI: 10.1002/art.20254] [Citation(s) in RCA: 430] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To investigate the release of interferon-alpha (IFN alpha)-inducing material by necrotic or apoptotic cells, its properties, and the necessity of autoantibodies from systemic lupus erythematosus (SLE) patients for the interferogenic activity. METHODS U937 monocytic leukemia cells or peripheral blood mononuclear cells (PBMCs) were rendered necrotic by freeze-thawing or apoptotic by treatment with ultraviolet light. Cell culture supernatants from these cells and IgG from SLE patients (SLE IgG) were added to cultures of normal PBMCs or purified plasmacytoid dendritic cells (PDCs). The importance of nucleic acids for IFN alpha induction was investigated by RNase and DNase treatment. The IFN alpha levels were measured by immunoassay. RESULTS Both necrotic and apoptotic U937 cells released material that, combined with SLE IgG, induced IFN alpha production in PDCs. The release from apoptotic cells occurred with a 16-hour delay, in late apoptosis. Also, normal PBMCs released IFN alpha-inducing material, but only during necrosis. The interferogenic activity of the necrotic material required the presence of RNA, while both RNA and DNA were important in the apoptotic material. In both cases, the presence of SLE IgG was necessary, and its activity correlated with the presence of antibodies to RNA-binding proteins, but not anti-DNA antibodies. CONCLUSION Necrotic and late apoptotic cells release material that, combined with SLE IgG, induces production of IFN alpha in PDCs. The IFN alpha inducers probably consist of immune complexes (ICs) containing RNA and possibly DNA as essential interferogenic components. The presence of such interferogenic ICs could explain the ongoing production of IFN alpha in SLE and could be of etiopathogenic importance.
Collapse
Affiliation(s)
- Tanja Lövgren
- Immunology V, Biomedical Center, Uppsala University, Uppsala, Sweden.
| | | | | | | | | |
Collapse
|
1645
|
Pfeffer LM, Kim JG, Pfeffer SR, Carrigan DJ, Baker DP, Wei L, Homayouni R. Role of Nuclear Factor-κB in the Antiviral Action of Interferon and Interferon-regulated Gene Expression. J Biol Chem 2004; 279:31304-11. [PMID: 15131130 DOI: 10.1074/jbc.m308975200] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Interferons (IFNs) play critical roles in host defense by modulating the expression of various genes via tyrosine phosphorylation of STAT transcription factors. IFN-alpha/beta activates another important transcription factor, nuclear factor-kappaB (NF-kappaB), but its role in IFN-mediated activity is poorly understood. Sensitivity to the antiviral and gene-inducing effects of IFN was examined in normal fibroblasts and in NF-kappaB knockout fibroblasts from p50- and p65-null mice. Antiviral assays demonstrated that NF-kappaB knockout fibroblasts were sensitized to the antiviral action of IFN. Moreover, analysis of IFN-stimulated gene expression by real-time PCR demonstrated selective effects of NF-kappaB on gene expression. Our results demonstrate that a subset of IFN-stimulated genes is regulated through an NF-kappaB-dependent pathway and that NF-kappaB may regulate the sensitivity of cells to IFN-mediated antiviral activity.
Collapse
Affiliation(s)
- Lawrence M Pfeffer
- Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38103, USA.
| | | | | | | | | | | | | |
Collapse
|
1646
|
Abstract
We propose a model where autoimmunity can be viewed as a dynamic system driven by opposite vectors IFN-alpha/beta and TNF. These cytokines drive differentiation of distinct types of DCs, TNF-DCs, or IFN-DCs, which present different antigens leading to distinct autoimmune responses. When balanced, both cytokines synergize in protective immunity. When one of the cytokines prevails, autoimmunity occurs, Type I interferons (IFN-alpha/beta) playing a major role in systemic lupus erythematosus (SLE) and TNF playing a major role in rheumatoid arthritis. This model complements the Type 1/Type 2 paradigm. Therefore, immunity can be viewed as a dynamic system driven by two sets of opposite vectors: IFN-alpha/beta/TNF and IFN-gamma/IL-4.
Collapse
Affiliation(s)
- Jacques Banchereau
- Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, TX 75204 USA
| | | | | |
Collapse
|
1647
|
Peterson KS, Huang JF, Zhu J, D’Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004. [DOI: 10.1172/jci200419139] [Citation(s) in RCA: 190] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
1648
|
Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. ACTA ACUST UNITED AC 2004; 199:1631-40. [PMID: 15197227 PMCID: PMC2212813 DOI: 10.1084/jem.20031942] [Citation(s) in RCA: 392] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Dendritic cell (DC) activation by nucleic acid-containing immunoglobulin (Ig)G complexes has been implicated in systemic lupus erythematosus (SLE) pathogenesis. However, the mechanisms responsible for activation and subsequent disease induction are not completely understood. Here we show that murine DCs are much more effectively activated by immune complexes that contain IgG bound to chromatin than by immune complexes that contain foreign protein. Activation by these chromatin immune complexes occurs by two distinct pathways. One pathway involves dual engagement of the Fc receptor FcgammaRIII and Toll-like receptor (TLR)9, whereas the other is TLR9 independent. Furthermore, there is a characteristic cytokine profile elicited by the chromatin immune complexes that distinguishes this response from that of conventional TLR ligands, notably the induction of BAFF and the lack of induction of interleukin 12. The data establish a critical role for self-antigen in DC activation and explain how the innate immune system might drive the adaptive immune response in SLE.
Collapse
Affiliation(s)
- Melissa W Boulé
- Renal Section, Department of Medicine, Boston University School of Medicine, EBRC 5th Floor, 650 Albany Street, Boston, MA 02118, USA
| | | | | | | | | | | |
Collapse
|
1649
|
Häupl T, Krenn V, Stuhlmüller B, Radbruch A, Burmester GR. Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies. Arthritis Res Ther 2004; 6:140-6. [PMID: 15225356 PMCID: PMC464885 DOI: 10.1186/ar1194] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2004] [Revised: 04/27/2004] [Accepted: 05/12/2004] [Indexed: 01/03/2023] Open
Abstract
The deciphering of the sequence of the human genome has raised the expectation of unravelling the specific role of each gene in physiology and pathology. High-throughput technologies for gene expression profiling provide the first practical basis for applying this information. In rheumatology, with its many diseases of unknown pathogenesis and puzzling inflammatory aspects, these advances appear to promise a significant advance towards the identification of leading mechanisms of pathology. Expression patterns reflect the complexity of the molecular processes and are expected to provide the molecular basis for specific diagnosis, therapeutic stratification, long-term monitoring and prognostic evaluation. Identification of the molecular networks will help in the discovery of appropriate drug targets, and permit focusing on the most effective and least toxic compounds. Current limitations in screening technologies, experimental strategies and bioinformatic interpretation will shortly be overcome by the rapid development in this field. However, gene expression profiling, by its nature, will not provide biochemical information on functional activities of proteins and might only in part reflect underlying genetic dysfunction. Genomic and proteomic technologies will therefore be complementary in their scientific and clinical application.
Collapse
Affiliation(s)
- Thomas Häupl
- Department of Rheumatology, Charité, Berlin, Germany.
| | | | | | | | | |
Collapse
|
1650
|
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Moser K, Ortmann WA, Espe KJ, Balasubramanian S, Hughes KM, Chan JP, Begovich A, Chang SYP, Gregersen PK, Behrens TW. Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation. Genes Immun 2004; 5:347-53. [PMID: 15175644 DOI: 10.1038/sj.gene.6364098] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Monitoring of gene and protein expression in peripheral blood cells has significant potential for improving the diagnosis and therapy of many human diseases. As genomic-scale microarray and proteomic technologies are applied to peripheral blood, it is important to consider the variables that may affect interpretation of data. Here we report experiments performed to identify genes that are particularly sensitive to ex vivo handling prior to RNA extraction for gene expression microarrays or quantitative real-time RT-PCR assays. We examined Affymetrix gene expression in samples from eight normal individuals where blood was processed for RNA either immediately after blood draw or the next day following overnight incubation. These studies identified hundreds of genes that are sensitive to ex vivo handling of blood, and suggest that this is an important variable to consider when designing and interpreting human PBMC experiments.
Collapse
Affiliation(s)
- E C Baechler
- Department of Medicine, University of Minnesota, Minneapolis, 55455, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|